8160 South Highland Drive
About Co-DiagnosticsCo-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our molecular diagnostics development platform is marketed under the brand name Co-Dx™. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide. YEAR FOUNDED:
Founder and CEO: Dwight (Ike) Egan
Founder and CTO: Brent Satterfield
Tweets by Co-Diagnostics
40 articles with Co-Diagnostics
Conference hosted at U.S. corporate headquarters to include training for distributors and end-users of Company’s diagnostic, research, and vector-control products
Logix Smart™ ZDC Test now available for export from the United States as a CE-marked IVD
Co-Diagnostics Completes Submission of CE Mark Registration for Zika/Dengue/Chikungunya Multiplex Test
Company’s multiplexed Logix Smart™ ZDC Test to be available for purchase with CE mark in March 2019
Co-Diagnostics, Inc. announced that it has received written notice from the Nasdaq Stock Market Listing Qualifications Staff on February 19, 2019, indicating that the Company has regained compliance with the minimum stockholders’ equity requirement as set forth in Nasdaq Capital Markets Listing Rule 5550.
Trainings will be conducted for staff and customers of Laboratorios Franja, including demonstrations of Company’s vector control products
Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced the closing of its previously announced offering.
The closing of the offering is expected to occur on or about February 4, 2019, subject to the satisfaction of customary closing conditions.
Transaction included $3M of preferred shares, and the elimination of $2M of debt
Presentation coincided with launch of a private-label CoPrimer product
Company Senior Research Scientist will be a guest speaker of LGC, Biosearch
Co-Diagnostics CEO to Discuss Progress and Forecasts in a Lytham Partners’ Virtual Investors Conference Presentation on Tuesday, December 4, 2018 at 4:00 pm ET
Co-Diagnostics, Inc. announced today that it will discuss the Company’s recent progress and upcoming sales expectations on Tuesday, December 4, 2018 at 4:00 pm ET (3:00 pm CT) in a Lytham Partners’ Virtual Investors Conference Presentation.
Co-Diagnostics, Inc. to Conduct Product Training Seminars with Distributor and Customers in the Dominican Republic
Trainings will be conducted for staff and customers of Laboratorios Franja, followed by launch of Company’s products in DR
Co-Diagnostics agrees to license CoPrimers™ for use in agricultural applications
Co-Diagnostics, Inc. announced today that it will be offering a presentation of its mosquito vector control program at the 71st Annual Utah Mosquito Abatement Association conference in Ogden, Utah on October 29, 2018.
Company’s Logix Smart™ Zika Test to be available for purchase with CE mark
Co-Diagnostics, Inc. announced today that it has been awarded a patent from the United States Patent and Trademark Office related to the Company’s CoPrimer™ platform technology.
Co-Diagnostics, Inc. announced today that it will be presenting at the Fourth Annual Robins Equity Research Roundup, held September 25 – 26, 2018 near Portland, Oregon.
As the Company approaches commercialization of selected molecular diagnostic tests, Latin America joins India and the Caribbean region as important target markets for its products.
Co-Diagnostics, Inc. announced today the filing of a shelf registration statement on Form S-3 with the Securities and Exchange Commission
Company to accelerate initiatives in infectious disease, liquid biopsy and SNP multiplexing